Amalgamated Bank Sells 1,024 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)

Amalgamated Bank cut its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 2.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,829 shares of the biopharmaceutical company’s stock after selling 1,024 shares during the quarter. Amalgamated Bank’s holdings in Cytokinetics were worth $3,409,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of CYTK. Natixis Advisors L.P. lifted its holdings in shares of Cytokinetics by 43.6% in the 4th quarter. Natixis Advisors L.P. now owns 62,962 shares of the biopharmaceutical company’s stock worth $5,256,000 after acquiring an additional 19,124 shares during the last quarter. Fisher Asset Management LLC bought a new position in shares of Cytokinetics during the fourth quarter valued at about $44,747,000. First Trust Direct Indexing L.P. purchased a new position in shares of Cytokinetics in the fourth quarter worth about $333,000. Victory Capital Management Inc. lifted its stake in shares of Cytokinetics by 1,040.4% in the 4th quarter. Victory Capital Management Inc. now owns 191,654 shares of the biopharmaceutical company’s stock valued at $16,001,000 after acquiring an additional 174,848 shares during the last quarter. Finally, Sage Rhino Capital LLC purchased a new stake in Cytokinetics during the 4th quarter valued at about $204,000.

Insider Buying and Selling

In other Cytokinetics news, Director John T. Henderson sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $76.48, for a total value of $382,400.00. Following the sale, the director now directly owns 42,632 shares of the company’s stock, valued at $3,260,495.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Cytokinetics news, Director John T. Henderson sold 10,562 shares of the firm’s stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $64.54, for a total transaction of $681,671.48. Following the completion of the sale, the director now directly owns 32,070 shares in the company, valued at approximately $2,069,797.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John T. Henderson sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $76.48, for a total transaction of $382,400.00. Following the completion of the transaction, the director now owns 42,632 shares in the company, valued at approximately $3,260,495.36. The disclosure for this sale can be found here. Insiders have sold 96,318 shares of company stock worth $6,701,940 in the last 90 days. Insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CYTK shares. Oppenheimer decreased their price target on Cytokinetics from $107.00 to $106.00 and set an “outperform” rating on the stock in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $108.00 price objective on shares of Cytokinetics in a research note on Thursday. Truist Financial reissued a “buy” rating and issued a $86.00 target price on shares of Cytokinetics in a research note on Monday, April 8th. Mizuho dropped their price objective on Cytokinetics from $103.00 to $99.00 and set a “buy” rating for the company in a report on Wednesday, March 6th. Finally, UBS Group cut Cytokinetics from a “buy” rating to a “neutral” rating and boosted their target price for the company from $61.00 to $92.00 in a research note on Wednesday, January 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $81.60.

Cytokinetics Trading Down 1.9 %

Shares of CYTK stock opened at $64.02 on Friday. The company’s fifty day moving average price is $67.65 and its 200-day moving average price is $61.68. The stock has a market cap of $6.70 billion, a PE ratio of -11.75 and a beta of 0.72. Cytokinetics, Incorporated has a 12 month low of $25.98 and a 12 month high of $110.25.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.17). The business had revenue of $0.84 million for the quarter, compared to analyst estimates of $0.91 million. During the same quarter in the previous year, the business posted ($1.38) EPS. The business’s revenue for the quarter was down 81.8% on a year-over-year basis. On average, sell-side analysts forecast that Cytokinetics, Incorporated will post -4.5 earnings per share for the current fiscal year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.